HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Revance Therapeutics (RVNC) but lowers the price target from $12 to $11.
May 13, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revance Therapeutics' price target was lowered from $12 to $11 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target might initially concern investors, potentially putting downward pressure on the stock. However, maintaining a Buy rating suggests underlying confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as the market digests both the lowered target and the continued endorsement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100